Preliminary clinical evidence that targeting this pathway may provide a novel treatment to slow the progression of AD comes from a Phase 2a study with the Lp-PLA2 inhibitor, rilapladib (SB659032) [8]. Here, PLA2G7 is linked to Alzheimer disease.